Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Radiation Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1591742

This article is part of the Research TopicArtificial Intelligence-Assisted Radiotherapy for Pelvic and Abdominal MalignanciesView all articles

Machine Learning-Based Radiomics for Bladder Cancer Staging: Evaluating the Role of Imaging Timing in Differentiating T2 from T3 Disease

Provisionally accepted
Christoph  G LissonChristoph G Lisson1,2*Friedemann  ZengerlingFriedemann Zengerling3Luisa  GalleeLuisa Gallee1Konstantin  MüllerKonstantin Müller1Sabitha  ManojSabitha Manoj1Hanna  StöcklHanna Stöckl3Christian  BolenzChristian Bolenz3Meinrad  BeerMeinrad Beer1Michael  GötzMichael Götz1Catharina  Sylvia LissonCatharina Sylvia Lisson1,2*
  • 1Department of Diagnostic and Interventional Radiology, Ulm University Medical Center, Ulm, Germany
  • 2University of Ulm, Ulm, Baden-Wurttemberg, Germany
  • 3Department of Urology, University Hospital of Ulm, Ulm, Germany

The final, formatted version of the article will be published soon.

Objectives: Accurate preoperative staging of bladder cancer is essential for therapeutic decision-making, particularly in distinguishing between organconfined (T2) and extravesical (T3) disease. This study aimed to develop a CT-based radiomics model to differentiate T2 from T3 tumors and to evaluate the impact of imaging timing relative to transurethral resection of the bladder (TURB) on model performance. Additionally, we assessed the added diagnostic value of integrating routine clinical biomarkers.Methods: In this retrospective study, 97 patients with histologically confirmed bladder cancer who underwent TURB followed by contrast-enhanced CT were included. Tumor segmentation was performed using a semi-automated threedimensional approach, and radiomic features were extracted according to IBSI standards. A random forest classifier was trained to distinguish between T2 and T3 tumors. Patients were stratified according to the interval between TURB and CT imaging (≤14 days vs >14 days). Performance metrics were assessed for both radiomics-only and combined clinical-radiomics models. Clinical variables included preoperative creatinine, hemoglobin, arterial hypertension, diabetes mellitus, smoking status, and tumor size.Results: The radiomics-only model achieved an AUC of 0.68 in Cohort 1 (≤14 days post-TURB). In Cohort 2 (>14 days post-TURB), model performance improved with an AUC of 0.80. The combined clinical-radiomics model further enhanced performance, yielding an AUC of 0.76 in Cohort 1 and 0.82 in Cohort 2. Delayed imaging was associated with increased radiomic feature stability and improved classification accuracy, suggesting a potential benefit of temporal separation from post-surgical tissue changes.Conclusion: This study demonstrates the feasibility of CT-based radiomics using full-volume 3D tumor segmentation to distinguish between T2 and T3 bladder cancer. The integration of clinical biomarkers and consideration of imaging timing significantly improved model performance. These findings support the development of temporally optimized, multimodal prediction models for individualized bladder cancer staging and treatment planning.

Keywords: Radiomics, machine learning, Bladder cancer, Tumor staging, computed tomography, artificial intelligence, Image-based biomarkers

Received: 11 Mar 2025; Accepted: 11 Aug 2025.

Copyright: © 2025 Lisson, Zengerling, Gallee, Müller, Manoj, Stöckl, Bolenz, Beer, Götz and Lisson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Christoph G Lisson, Department of Diagnostic and Interventional Radiology, Ulm University Medical Center, Ulm, 89081, Germany
Catharina Sylvia Lisson, Department of Diagnostic and Interventional Radiology, Ulm University Medical Center, Ulm, 89081, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.